News & Information | START In The News

May 16th, 2013
The Wall Street Journal
By: PRESS RELEASE

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small molecule antagonist of IAP proteins, has been selected for oral presentation at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held from May 31- June 4 in Chicago, IL.

Results will also be presented on two Genentech (Roche) sponsored Erivedge (vismodegib) studies, including an 18-month update of the pivotal ERIVANCE BCC clinical study, as well as an interim analysis of 300 patients in the ongoing STEVIE study. Data from both Erivedge studies will be included as part of a melanoma/skin cancers poster discussion session.

Additional information on the sessions can be found below and abstracts can be accessed at www.ASCO.org.

 
Oral Presentation Sessions: 
 
Date/Time:                  Sunday, June 2, 2013, 9:00 AM -- 9:15 AM CT 
Location:                                      S406 
                        Developmental Therapeutics - Clinical Pharmacology 
Track:                             and Experimental Therapeutics 
                         Phase I study of safety and pharmacokinetics (PK) 
                        of GDC-0917, an antagonist of inhibitor of apoptosis 
                       (IAP) proteins in patients (Pts) with refractory solid 
Presentation Title:                     tumors or lymphoma. 
Presenter:                             Anthony Tolcher, M.D. 
Abstract Number:                                                         2503 
 
Poster Discussion Sessions: 
 
Date/Time:                       Monday, June 3, 2013, 8:00 AM -- 12:00 PM CT 
Location:                                                                S405 
                           Vismodegib, a Hedgehog pathway inhibitor (HPI), in 
                           advanced basal cell carcinoma (aBCC): STEVIE study 
Presentation Title:                         interim analysis in 300 patients. 
Presenter:                                            Jean Jacques Grob, M.D. 
Abstract Number:                                                         9036 
Poster Board:                                                              24 
 
Date/Time:                       Monday, June 3, 2013, 8:00 AM -- 12:00 PM CT 
Location:                                                                S405 
                      Long-term safety and efficacy of vismodegib in patients 
                          with advanced basal cell carcinoma (aBCC): 18-month 
Presentation Title:                 update of the pivotal ERIVANCE BCC study. 
Presenter:                                    Aleksandar Sekulic, M.D., Ph.D. 
Abstract Number:                                                         9037 
Poster Board:                                                              25 
 

About Curis, Inc.

Curis is an oncology-focused company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge(R) is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/HER2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information: 
         Michael P. Gray 
         Chief Financial Officer 
         Curis, Inc. 
         617-503-6632 
         mgray@curis.com 
The Wall Street Journal news department was not involved in the creation of this content.